ELI-002
Elicio Therapeutics
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'pancreatic', 'eli-002 ']
tomorrow morning, the results of amplify-201, a first-in-human safety &amp; efficacy trial of adjuvant eli-002 2p immunotherapy for patients w/ high-relapse risk with kras g12d- or g12r-mutated pancreatic &amp; crc will be discussed! #asco23 stay tuned! 
We FIGHT to cure colorectal cancer and serve as #RelentlessChampions of hope for all affected by this disease.